Astellas and Pfizer's Xtandi plus ADT showed a decrease in mortality risk in a metastatic hormone-sensitive prostate cancer ...

The aggressiveness of a cancer is based on several factors, including the tumor's grade and stage, and the cells' genetic ...

New research reveals prostate cancer survivors face a significant long-term risk of developing a third primary cancer, with a ...

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center named Top 5 "Best Hospital" in ...

Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of ...

Forthcoming press releases will feature additional notable oral abstracts. More information on all MD Anderson ASCO Annual ...

Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States ...

Donn Young is the former director of the Ohio State University Comprehensive Cancer Center Biostatistics Unit where he spent ...

The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to ...

Experts explain the science behind Biden's advanced prostate cancer diagnosis, including how common it is and what treatments are available.

Ed Burgess, diagnosed with stage IV prostate cancer, shares his journey of survival thanks to a combination of hormone therapy and the drug enzalutamide, highlighting the personal impact of research ...

Developing tests that better identify patients at risk of dying from prostate cancer can decrease overtreatment. In the ...